Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Discontinued Operations (2022 - 2023)

Marker Therapeutics (MRKR) has disclosed Cash from Discontinued Operations for 2 consecutive years, with 62938.0 as the latest value for Q4 2023.

  • On a quarterly basis, Cash from Discontinued Operations rose 97.14% to 62938.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 4924972.0, a N/A change, with the full-year FY2023 number at 6098899.0, down 11.73% from a year prior.
  • Cash from Discontinued Operations was 62938.0 for Q4 2023 at Marker Therapeutics, up from 260281.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 62938.0 in Q4 2023 to a low of 2399993.0 in Q3 2022.